Records containing: Stage III Renal Cell Cancer AJCC v8
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study results posted · 2026-08-20Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
-
CLINICAL_TRIALS study record update · 2026-04-27Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)
-
CLINICAL_TRIALS study record update · 2026-04-24A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
-
CLINICAL_TRIALS study record update · 2026-04-21A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
-
CLINICAL_TRIALS study record update · 2026-04-20WINSHIP4955-20: Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-04-15Combination Nivolumab and Ipilimumab With and Without Camu Camu in First Line Treatment of Metastatic Renal Cell Carcinoma
-
CLINICAL_TRIALS study record update · 2026-04-13PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
-
CLINICAL_TRIALS study record update · 2026-04-13Pilot Phase II Trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT)
-
CLINICAL_TRIALS study record update · 2026-04-13A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
-
CLINICAL_TRIALS study record update · 2026-04-08Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
-
CLINICAL_TRIALS study record update · 2026-04-03Phase 2 Clinical Evaluation of Combination Immunotherapy for Renal Cell Carcinoma
-
CLINICAL_TRIALS study record update · 2026-03-23Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection
-
CLINICAL_TRIALS study record update · 2026-03-18An Open-label, Single-Center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Malignancies After Progression on PD-1 or PD-L1 Targeted Antibodies
-
CLINICAL_TRIALS study record update · 2026-03-12A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)
-
CLINICAL_TRIALS study record update · 2026-03-12Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
-
CLINICAL_TRIALS study record update · 2026-03-05A Phase II Study of Lenvatinib Plus Everolimus Versus Cabozantinib in Patients With Metastatic Renal Cell Carcinoma That Progressed on A PD-1/PD-L1 Checkpoint Inhibitor
-
CLINICAL_TRIALS study record update · 2026-03-05Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Cabozantinib/Nivolumab for Patients With Metastatic Renal Cell Carcinoma
-
CLINICAL_TRIALS study record update · 2026-02-27A Randomized Study of Nivolumab and Ipilimumab With and Without EXL01 in First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC)
-
CLINICAL_TRIALS study record update · 2026-02-12Knight Cancer Institute Study of Histology-Agnostic Immunotherapy With Focus on Timing: - Knight SHIFT - A Prospective, Multi-Histology Pragmatic Study
-
CLINICAL_TRIALS study record update · 2026-02-03Phase III Double Blinded Trial of Immune-Based Therapy With a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]
-
CLINICAL_TRIALS study record update · 2026-01-14Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
-
CLINICAL_TRIALS study record update · 2026-01-09Phase II Trial of Ixazomib Combined With Gemcitabine and Doxorubicin in Patients With Renal Medullary Carcinoma
-
CLINICAL_TRIALS study record update · 2025-12-24A Phase 1 Safety and Efficacy Study of STIL101 for Injection in Locally Advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Renal Cell Carcinoma, Cervical Cancer, and Melanoma
-
CLINICAL_TRIALS study record update · 2025-12-05Remote Perioperative Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
-
CLINICAL_TRIALS study record update · 2025-12-04Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program